Home › Companies › COHERUS BIOSCIENCES INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and COHERUS BIOSCIENCES INC.’s Form 8-K, filed June 4, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 29, 2024: 6 items on COHERUS BIOSCIENCES INC.’s Form 8-K, filed June 4, 2024: 3 elected · 3 approved.
Significant dissent: 1 director (21.3% against); 1 equity or compensation plan (33.4% against).
Notable dissent: 2 directors (19.4%, 17.5% against); 1 say-on-pay vote (71.0% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore COHERUS BIOSCIENCES INC. in the interactive database Compare manager voting policies
These tallies are COHERUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Lee N. Newcomer, MD | 48,281,843 | -- | -- | 10,274,659 | -- | 82% | Elected | — |
| Elect Director: Charles W. Newton | 47,197,934 | -- | -- | 11,358,568 | -- | 81% | Elected | — |
| Elect Director: Kimberly J. Tzoumakas | 46,098,866 | -- | -- | 12,457,636 | -- | 79% | Elected | — |
| 2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 | 79,827,737 | 551,990 | 147,169 | -- | 0 | 99.3% | Approved | — |
| 3. Non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote) | 40,280,182 | 16,457,046 | 1,819,274 | -- | 21,970,394 | 71% | Approved | — |
| 4. The amendment and restatement of the Company's 2014 Equity Incentive Award Plan | 37,628,123 | 18,905,881 | 2,022,498 | -- | 21,970,394 | 67% | Approved | — |
Source: COHERUS BIOSCIENCES INC., Form 8-K, filed with the SEC on June 4, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
143 asset managers disclosed a vote on at least one COHERUS BIOSCIENCES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Charles W. Newton
COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Charles W. Newton”): 47,197,934 for, 11,358,568 withheld, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class I director nominees below, Lee N. Newcomer, MD, Charles W. Newton and Kimberly J. Tzoumakas, to the Board to hold office until the 2027 annual meeting of stockholders or until their successors are elected.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 10,337,275 for, 137,264 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,847,313 | 0 | 0 | 0 | For |
| BlackRock | 1,605,551 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| Charles Schwab | 689,456 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 168,000 | 0 | 0 | 0 | For |
| Equitable | 164,003 | 0 | 0 | 0 | For |
| New York Life | 154,248 | 0 | 0 | 0 | For |
| SEI | 151,620 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 125,858 | 0 | 0 | 0 | For |
| Fidelity | 110,917 | 0 | 0 | 0 | For |
| MFS | 98,019 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 83,905 | Withhold |
| Northern Trust | 65,347 | 0 | 0 | 0 | For |
| John Hancock | 38,068 | 0 | 0 | 0 | For |
| Pacific Life | 33,880 | 0 | 0 | 0 | For |
| Transamerica | 31,088 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 0 | 29,534 | Withhold |
| ProShares | 26,494 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 23,391 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 14,995 | 0 | 0 | 0 | For |
| DWS | 14,337 | 0 | 0 | 0 | For |
| Principal | 14,075 | 0 | 0 | 0 | For |
| Victory Capital | 13,979 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,430 | 0 | 0 | 0 | For |
| Voya | 12,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Kimberly J. Tzoumakas
COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kimberly J. Tzoumakas”): 46,098,866 for, 12,457,636 withheld, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class I director nominees below, Lee N. Newcomer, MD, Charles W. Newton and Kimberly J. Tzoumakas, to the Board to hold office until the 2027 annual meeting of stockholders or until their successors are elected.”
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 10,120,373 for, 354,166 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,847,313 | 0 | 0 | 0 | For |
| BlackRock | 1,605,551 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| Charles Schwab | 689,456 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 168,000 | Withhold |
| Equitable | 17,503 | 0 | 0 | 146,500 | Mixed |
| New York Life | 154,248 | 0 | 0 | 0 | For |
| SEI | 151,620 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 125,858 | 0 | 0 | 0 | For |
| Fidelity | 110,917 | 0 | 0 | 0 | For |
| MFS | 98,019 | 0 | 0 | 0 | For |
| Lincoln Financial | 83,905 | 0 | 0 | 0 | For |
| Northern Trust | 65,347 | 0 | 0 | 0 | For |
| John Hancock | 38,068 | 0 | 0 | 0 | For |
| Pacific Life | 33,880 | 0 | 0 | 0 | For |
| Transamerica | 31,088 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 0 | 29,534 | Withhold |
| ProShares | 26,494 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 23,391 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 14,995 | 0 | 0 | 0 | For |
| DWS | 14,337 | 0 | 0 | 0 | For |
| Principal | 14,075 | 0 | 0 | 0 | For |
| Victory Capital | 13,979 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,430 | 0 | 0 | 0 | For |
| Voya | 12,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Lee N. Newcomer, MD
COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Lee N. Newcomer, MD”): 48,281,843 for, 10,274,659 withheld, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class I director nominees below, Lee N. Newcomer, MD, Charles W. Newton and Kimberly J. Tzoumakas, to the Board to hold office until the 2027 annual meeting of stockholders or until their successors are elected.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 10,434,876 for, 39,663 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,847,313 | 0 | 0 | 0 | For |
| BlackRock | 1,605,551 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| Charles Schwab | 689,456 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 168,000 | 0 | 0 | 0 | For |
| Equitable | 164,003 | 0 | 0 | 0 | For |
| New York Life | 154,248 | 0 | 0 | 0 | For |
| SEI | 151,620 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 125,858 | 0 | 0 | 0 | For |
| Fidelity | 110,917 | 0 | 0 | 0 | For |
| MFS | 98,019 | 0 | 0 | 0 | For |
| Lincoln Financial | 83,905 | 0 | 0 | 0 | For |
| Northern Trust | 65,347 | 0 | 0 | 0 | For |
| John Hancock | 38,068 | 0 | 0 | 0 | For |
| Pacific Life | 33,880 | 0 | 0 | 0 | For |
| Transamerica | 31,088 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 0 | 29,534 | Withhold |
| ProShares | 26,494 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 23,391 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 14,995 | 0 | 0 | 0 | For |
| DWS | 14,337 | 0 | 0 | 0 | For |
| Principal | 14,075 | 0 | 0 | 0 | For |
| Victory Capital | 13,979 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,430 | 0 | 0 | 0 | For |
| Voya | 12,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
67% Approved · of votes cast
Description as filed by funds: To approve the amendment and restatement of the Company's 2014 Equity Incentive Award Plan (the "2014 Plan").
COHERUS BIOSCIENCES INC.’s own tally for this item (“4. The amendment and restatement of the Company's 2014 Equity Incentive Award Plan”): 37,628,123 for, 18,905,881 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the amendment and restatement of the Company's 2014 Equity Incentive Award Plan.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 9,596,383 for, 1,847,396 against, 29,534 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,847,313 | 0 | 0 | 0 | For |
| BlackRock | 1,605,551 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,000,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 900,000 | 0 | 0 | Against |
| Charles Schwab | 689,456 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 168,000 | 0 | 0 | Against |
| Equitable | 17,503 | 146,500 | 0 | 0 | Mixed |
| New York Life | 0 | 154,248 | 0 | 0 | Against |
| SEI | 151,620 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 125,858 | 0 | 0 | 0 | For |
| Fidelity | 91,739 | 19,178 | 0 | 0 | Mixed |
| MFS | 0 | 98,019 | 0 | 0 | Against |
| Lincoln Financial | 0 | 83,905 | 0 | 0 | Against |
| Northern Trust | 0 | 65,347 | 0 | 0 | Against |
| John Hancock | 0 | 38,068 | 0 | 0 | Against |
| Pacific Life | 33,880 | 0 | 0 | 0 | For |
| Transamerica | 0 | 31,088 | 0 | 0 | Against |
| AuguStar | 0 | 0 | 29,534 | 0 | Abstain |
| ProShares | 0 | 26,494 | 0 | 0 | Against |
| Bridge Builder Trust | 23,391 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 14,995 | 0 | 0 | Against |
| DWS | 0 | 14,337 | 0 | 0 | Against |
| Principal | 0 | 14,075 | 0 | 0 | Against |
| Victory Capital | 0 | 13,979 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 13,430 | 0 | 0 | Against |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
Combines 16 wordings of this item as funds reported it.
71% Approved · of votes cast
Prior year: 94.5% for (June 7, 2023 meeting) ▼ 23.5 pts
Description as filed by funds: To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).
COHERUS BIOSCIENCES INC.’s own tally for this item (“3. A non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote)”): 40,280,182 for, 16,457,046 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,847,313 | 0 | 0 | 0 | For |
| BlackRock | 1,605,551 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,000,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| Charles Schwab | 689,456 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 168,000 | 0 | 0 | Against |
| Equitable | 164,003 | 0 | 0 | 0 | For |
| New York Life | 154,248 | 0 | 0 | 0 | For |
| SEI | 151,620 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 125,858 | 0 | 0 | 0 | For |
| Fidelity | 110,917 | 0 | 0 | 0 | For |
| MFS | 98,019 | 0 | 0 | 0 | For |
| Lincoln Financial | 83,905 | 0 | 0 | 0 | For |
| Northern Trust | 65,347 | 0 | 0 | 0 | For |
| John Hancock | 38,068 | 0 | 0 | 0 | For |
| Pacific Life | 33,880 | 0 | 0 | 0 | For |
| Transamerica | 31,088 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 29,534 | 0 | Abstain |
| ProShares | 26,494 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 23,391 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 14,995 | 0 | 0 | 0 | For |
| DWS | 14,337 | 0 | 0 | 0 | For |
| Principal | 14,075 | 0 | 0 | 0 | For |
| Victory Capital | 13,979 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,430 | 0 | 0 | 0 | For |
Fund voting reports, all 42 managers: 11,261,989 for, 181,690 against, 29,534 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 0 | 8,307,399 | 0 | 0 | Against |
| Temasek Holdings (Private) Ltd | 7,381,116 | 0 | 0 | 0 | For |
| BlackRock | 2,130,893 | 776 | 0 | 0 | For |
| C WorldWide Asset Management Fondsmaeglerselskab A/S | 0 | 1,928,464 | 0 | 0 | Against |
| Kohlberg Kravis Roberts & Co. L.P. | 1,499,499 | 0 | 0 | 0 | For |
| State Street | 1,071,264 | 368 | 0 | 0 | For |
| DISCIPLINED GROWTH INVESTORS INC /MN | 0 | 1,068,751 | 0 | 0 | Against |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 900,000 | 0 | 0 | 0 | For |
| Citadel | 831,593 | 0 | 0 | 0 | For |
| Charles Schwab | 822,338 | 0 | 0 | 0 | For |
| Clearline Capital LP | 784,449 | 0 | 0 | 0 | For |
| PEREGRINE CAPITAL MANAGEMENT LLC | 772,341 | 0 | 0 | 0 | For |
| Woodline Partners LP | 684,948 | 0 | 0 | 0 | For |
| Two Sigma | 498,032 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 496,573 | 0 | 0 | 0 | For |
| Northern Trust | 460,578 | 54 | 0 | 0 | For |
| Lazard | 387,700 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 326,479 | 0 | 0 | 0 | For |
| Vanguard | 325,674 | 0 | 0 | 0 | For |
| Wellington | 305,879 | 0 | 0 | 0 | For |
| Birchview Capital, LP | 256,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 194,038 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 168,000 | 0 | 0 | Against |
| SEI | 152,007 | 76 | 0 | 0 | For |
| AllianceBernstein | 146,500 | 0 | 0 | 0 | For |
Institutional-manager reports, all 115 managers: 21,683,010 for, 11,582,619 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.3% Approved · of votes cast
Prior year: 99.3% for (June 7, 2023 meeting) unchanged
Description as filed by funds: To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
COHERUS BIOSCIENCES INC.’s own tally for this item (“2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024”): 79,827,737 for, 551,990 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 11,444,695 for, 310 against, 29,534 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,847,313 | 0 | 0 | 0 | For |
| BlackRock | 1,605,551 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,000,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| Charles Schwab | 689,456 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 168,000 | 0 | 0 | 0 | For |
| Equitable | 164,003 | 0 | 0 | 0 | For |
| New York Life | 154,248 | 0 | 0 | 0 | For |
| SEI | 151,620 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 125,858 | 0 | 0 | 0 | For |
| Fidelity | 110,917 | 0 | 0 | 0 | For |
| MFS | 98,019 | 0 | 0 | 0 | For |
| Lincoln Financial | 83,905 | 0 | 0 | 0 | For |
| Northern Trust | 65,347 | 0 | 0 | 0 | For |
| John Hancock | 38,068 | 0 | 0 | 0 | For |
| Pacific Life | 33,880 | 0 | 0 | 0 | For |
| Transamerica | 31,088 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 29,534 | 0 | Abstain |
| ProShares | 26,494 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 23,391 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 14,995 | 0 | 0 | 0 | For |
| DWS | 14,337 | 0 | 0 | 0 | For |
| Principal | 14,075 | 0 | 0 | 0 | For |
| Victory Capital | 13,979 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,430 | 0 | 0 | 0 | For |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 114,725,740 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.10% |
| 2 | BlackRock | 1.40% |
| 3 | MUTUAL FUND SERIES TRUST | 0.87% |
| 4 | Delaware/Macquarie | 0.78% |
| 5 | Charles Schwab | 0.60% |
| 6 | BRIDGEWAY FUNDS INC | 0.15% |
| 7 | Equitable | 0.14% |
| 8 | New York Life | 0.13% |
| 9 | SEI | 0.13% |
| 10 | QUANTITATIVE MASTER SERIES LLC | 0.11% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Rubric Capital Management LP | 7.24% |
| 2 | Temasek Holdings (Private) Ltd | 6.43% |
| 3 | BlackRock | 1.86% |
| 4 | C WorldWide Asset Management Fondsmaeglerselskab A/S | 1.68% |
| 5 | Kohlberg Kravis Roberts & Co. L.P. | 1.31% |
| 6 | State Street | 0.93% |
| 7 | DISCIPLINED GROWTH INVESTORS INC /MN | 0.93% |
| 8 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 0.78% |
| 9 | Citadel | 0.72% |
| 10 | Charles Schwab | 0.72% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 10,459,986 | 9.12% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 10,321,107 | 9.00% | Form 13F, quarter ended March 31, 2024 |
| Entities associated with Temasek Holdings (Private) Limited | 7,381,116 | 6.43% | Proxy statement (DEF 14A), proxy filed April 15, 2024 |
| Ali J. Satvat | 3,036,576 | 2.65% | Proxy statement (DEF 14A), proxy filed April 15, 2024 |
| Citadel Advisors | 2,867,427 | 2.50% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 2,203,694 | 1.92% | Form 13F, quarter ended March 31, 2024 |
| State Street | 1,995,738 | 1.74% | Form 13F, quarter ended March 31, 2024 |
| Two Sigma | 1,462,013 | 1.27% | Form 13F, quarter ended March 31, 2024 |
| Millennium Management | 1,257,363 | 1.10% | Form 13F, quarter ended March 31, 2024 |
| Dennis M. Lanfear | 1,228,343 | 1.07% | Proxy statement (DEF 14A), proxy filed April 15, 2024 |
Percentages above are of 114,725,740 shares outstanding, as reported by COHERUS BIOSCIENCES INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At COHERUS BIOSCIENCES INC.'s shareholder meeting held May 29, 2024, in the 2023-2024 proxy season, 143 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 864 separate fund positions. On the most widely held item on that ballot — To vote on a non-binding, advisory basis to approve the compensation of the Company's named… — COHERUS BIOSCIENCES INC.'s filing reports the proposal as approved, with 71% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: COHERUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from COHERUS BIOSCIENCES INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
COHERUS BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “COHERUS BIOSCIENCES (CHRS) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/coherus-biosciences-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.